Comparison of [<sup>18</sup>F]FAPI-42 and [<sup>18</sup>F]FDG PET/CT in the evaluation of systemic vasculitis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 39601894.
- Also identified by DOI 10.1007/s00259-024-06986-2.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of fibroblast activation protein (FAP)-targeted imaging in systemic vasculitis is currently unclear. We aimed to evaluate the clinical value of fluorine-18-labeled FAP inhibitor 42 ([<sup>18</sup>F]FAPI-42) in patients with systemic vasculitis and to compare with [<sup>18</sup>F]fluorodeoxyglucose (FDG) imaging. Patients with systemic vasculitis who underwent dual-tracer PET/CT([<sup>18</sup>F]FDG and [<sup>18</sup>F]FAPI) imaging from September 2020 to March 2022 were retrospectively analyzed. Positive lesions are defined as vascular/extravascular lesions with increased tracer uptake above surrounding background, which cannot be attributed to the physiologic biodistribution of the radiotracer. The vascular/extravascular lesion detection rate and semiquantitative values (SUVmax, TBR<sub>blood</sub> and TBR<sub>liver</sub>) of [<sup>18</sup>F]FAPI and [<sup>18</sup>F]FDG were compared, and the correlation between the extent and range of tracer uptake and levels of inflammatory markers was investigated. Thirty patients (13 males and 17 females; mean age, 52.5 ± 17.2 years) with systemic vasculitis were included (17 large vessel vasculitis, 10 anti-neutrophil cytoplasmic antibody-associated vasculitis, 2 Behcet's disease and 1 polyarteritis nodosa). [<sup>18</sup>F]FDG PET/CT had positive findings in 93.3% (28/30) of patients, while [<sup>18</sup>F]FAPI PET/CT had positive findings in all patients (100%, P = 0.500). Compared with [<sup>18</sup>F]FDG PET/CT, [<sup>18</sup>F]FAPI PET/CT detected more lesions (161/168 vs. 145/168, P = 0.005), and more extensive vascular involvement in 60% (18/30) of patients. Although SUVmax did not differ significantly between [<sup>18</sup>F]FAPI and [<sup>18</sup>F]FDG (median, 5.94 vs. 5.46, P = 0.517), [<sup>18</sup>F]FAPI had higher TBR<sub>liver</sub> (median, 9.59 vs. 3.15, P < 0.001) and TBR<sub>blood</sub> (median, 5.45 vs. 4.20, P = 0.006). The total number of positive lesions in FAPI PET/CT show a moderate correlation with erythrocyte sedimentation rate (r<sub>s</sub> =0.478, P = 0.008) and C-reactive protein (r<sub>s</sub> =0.486, P = 0.006). After treatment, follow-up FAPI PET/CT of 6 patients showed decreased SUVmax, TBR and number of detected lesions, paralleling the clinical remission. [<sup>18</sup>F]FAPI PET/CT imaging is a promising imaging modality for the diagnosis and therapeutic monitoring of systemic vasculitis.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Fluorodeoxyglucose F18
- Systemic Vasculitis